New clinical features, opinion pieces and much more—outgoing Arthritis & Rheumatology Editor-in-Chief Daniel H. Solomon, MD, MPH, discusses how the journal has evolved and where it’s going.
Search results for: juvenile idiopathic arthritis
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
Youthful Exuberance: The Year in Review for Pediatric Rheumatology
WASHINGTON, D.C.—It is no small task to summarize an entire year’s worth of research accomplishments in any field of medicine, let alone one as complex as rheumatology. At ACR Convergence 2024, the Pediatric Year in Review not only provided a thoughtful summary, but also grouped advances along several different themes. Immune Health & More Jessica…
Weathering the Cytokine Storm: Macrophage Activation Syndrome in Adults & Children
Peter Nigrovic, MD, provides a practical guide to the diagnosis & treatment of macrophage activation syndrome (MAS) in children & adults.
The ABCs of RCTs
At this ACR Convergence 2024 session, experts discussed new and creative ways to design trials to account for real-world scenarios and to produce information relevant to practicing clinicians.
FDA Officials Discuss Extrapolation & Confusion Around Pediatric Therapies
A session at ACR Convergence 2024 addressed several recent drug approvals in pediatric rheumatology and a safety update for IL-1/IL-6 inhibitors.
Beth Jonas, MD, Brings Longstanding Workforce Expertise to Committee Chair Role
Dr. Jonas has long sought bold and innovative approaches to workforce challenges in rheumatology. As new chair of the Workforce Solutions Committee, she aims to increase the role of advanced practice providers in rheumatology practices and reduce wait times for specialty care.
Can Cultural Humility Conquer Systemic Inequity in Pediatric Rheumatology?
Doctors and patient advocates urged the rheumatology community to address the drastic inadequacies in care faced by marginalized people in a session held at ACR Convergence 2024.
The Great Pediatric Debate 2024: Cessation or Continuation of Biologics in sJIA Lung Disease?
Washington D.C.—At a Sunday, Nov. 17, Pediatrics Great Debate session of ACR Convergence, speakers argued whether patients with systemic juvenile idiopathic arthritis (sJIA) should continue their interleukin (IL) 1/IL-6 biologics if lung disease is suspected. Randy Q. Cron, MD, PhD, the director of the Division of Pediatric Rheumatology at the University of Alabama at Birmingham,…
Rheum After 5: Dr. Elizabeth Hazel, Olympian
Dr. Elizabeth Hazel reflects on her experience as a Canadian swimming competitor in the 1992 Summer Olympics.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 37
- Next Page »